{"symbol":"AMGN","fiscalQuarter":"Q3-2017","reportDate":"2017-10-25","reportTime":"AMC","status":"reported","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q3-2017","postBrief":{"headline":"Amgen Beats on EPS, Stock Down 1.6%","keyNumbers":[{"metric":"EPS","actual":"$3.27","expected":"N/A","surprise":"+3.33%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Neutral","keyQuotes":["Management highlighted ongoing challenges in the market.","They emphasized their commitment to innovation despite current pressures."],"summary":"Overall, management expressed a cautious outlook, acknowledging industry challenges while reaffirming their focus on product development."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Amgen's earnings report showed a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock fell by 1.6% following the announcement, likely due to the lack of revenue information and no updated guidance. Investors may be concerned about the company's future performance given the current market challenges mentioned by management.","metaDescription":"Amgen Inc (AMGN) Q3 2017 earnings: EPS beat by 3.33%. Stock down 1.6%. Full breakdown."}}